Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Stands Up To Trump Pressure With COVID-19 Vaccines Science Pledge

New US Poll Shows Public Distrust

Executive Summary

CEOs from the most advanced vaccines developers pledge to maintain standards – for the sake of safety, efficacy and public trust in vaccines.

You may also be interested in...



Pfizer's COVID-19 Vaccine Commercialization Plan Includes DTC Campaign

The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.

AstraZeneca CEO: 2020 Approval For COVID Vaccine Still Possible

While AZ awaits an independent review, its CEO maintains the vaccine could soon be back on track for a late 2020/early 2021 approval.

No EUA For COVID-19 Vaccines Prior To Trials Completion, Says India

The Indian regulator says it is not considering emergency use authorization for COVID-19 vaccines before completion of clinical trials, a stand validated by AstraZeneca halting trials of its vaccine candidate due to an adverse event in UK. Meanwhile, India has signed up for Phase III trials of Russia’s vaccine candidate

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel